A safety assessment of a fowlpox-vectored Mycoplasma gallisepticum vaccine in chickens.
A recombinant fowlpox virus vaccine expressing key protective Mycoplasma gallisepticum antigens could facilitate in the prevention both of fowlpox virus and M. gallisepticum infections. Vectormune FP-MG vaccine, a recombinant fowlpox virus expressing both M. gallisepticum 40k and mgc genes, was assessed for its safety in 8-wk-old specific-pathogen-free White Leghorn chickens. The vaccine virus was serially passaged 5 times by wing-web inoculation. Based on the postinoculation clinical observation, gross pathological examination of air sacs and peritoneum, genetic stability evaluation, virus shedding and tissue distribution detection, horizontal transmission ability determination, and protection against fowlpox virus challenge, the Vectormune FP-MG vaccine possesses a high level of safety.
Zhang
G Z
GZ
Department of Preventive Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing 100193, PR China. zhanggz@cau.edu.cn
Zhang
R
R
Zhao
H L
HL
Wang
X T
XT
Zhang
S P
SP
Li
X J
XJ
Qin
C Z
CZ
Lv
C M
CM
Zhao
J X
JX
Zhou
J F
JF
D000818:Animals; D001428:Bacterial Vaccines / Q000009:adverse effects* / Q000276:immunology; D002645:Chickens; D005587:Fowlpox virus; D009175:Mycoplasma Infections / Q000517:prevention & control / Q000662:veterinary*; D045686:Mycoplasma gallisepticum / Q000276:immunology*; D011201:Poultry Diseases / Q000517:prevention & control*; D013047:Specific Pathogen-Free Organisms; D014614:Vaccines, Synthetic / Q000276:immunology
D001428:Bacterial Vaccines; D014614:Vaccines, Synthetic